Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer.

Dischinger PS, Tovar EA, Essenburg CJ, Madaj ZB, Gardner EE, Callaghan ME, Turner AN, Challa AK, Kempston T, Eagleson B, Kesterson RA, Bronson RT, Bowman MJ, Graveel CR, Steensma MR.

NPJ Breast Cancer. 2018 Aug 30;4:29. doi: 10.1038/s41523-018-0080-8. eCollection 2018.

2.

Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors.

Peacock JD, Pridgeon MG, Tovar EA, Essenburg CJ, Bowman M, Madaj Z, Koeman J, Boguslawski EA, Grit J, Dodd RD, Khachaturov V, Cardona DM, Chen M, Kirsch DG, Maina F, Dono R, Winn ME, Graveel CR, Steensma MR.

Cancer Res. 2018 Jul 1;78(13):3672-3687. doi: 10.1158/0008-5472.CAN-17-3167. Epub 2018 May 2.

3.

Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities.

Lanning NJ, Castle JP, Singh SJ, Leon AN, Tovar EA, Sanghera A, MacKeigan JP, Filipp FV, Graveel CR.

Cancer Metab. 2017 Aug 22;5:6. doi: 10.1186/s40170-017-0168-x. eCollection 2017.

4.

MET in human cancer: germline and somatic mutations.

Tovar EA, Graveel CR.

Ann Transl Med. 2017 May;5(10):205. doi: 10.21037/atm.2017.03.64. Review.

5.

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.

Linklater ES, Tovar EA, Essenburg CJ, Turner L, Madaj Z, Winn ME, Melnik MK, Korkaya H, Maroun CR, Christensen JG, Steensma MR, Boerner JL, Graveel CR.

Oncotarget. 2016 Oct 25;7(43):69903-69915. doi: 10.18632/oncotarget.12065.

6.

UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.

Gilani RA, Phadke S, Bao LW, Lachacz EJ, Dziubinski ML, Brandvold KR, Steffey ME, Kwarcinski FE, Graveel CR, Kidwell KM, Merajver SD, Soellner MB.

Clin Cancer Res. 2016 Oct 15;22(20):5087-5096. Epub 2016 May 6.

7.

Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.

Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR, Sloane BF.

Clin Cancer Res. 2016 Feb 15;22(4):923-34. doi: 10.1158/1078-0432.CCR-15-0187. Epub 2015 Oct 2.

8.

Critical analysis of the potential for microRNA biomarkers in breast cancer management.

Graveel CR, Calderone HM, Westerhuis JJ, Winn ME, Sempere LF.

Breast Cancer (Dove Med Press). 2015 Feb 23;7:59-79. doi: 10.2147/BCTT.S43799. eCollection 2015. Review.

9.

Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer.

MacKenzie TA, Schwartz GN, Calderone HM, Graveel CR, Winn ME, Hostetter G, Wells WA, Sempere LF.

Am J Pathol. 2014 Dec;184(12):3217-25. doi: 10.1016/j.ajpath.2014.08.020. Epub 2014 Nov 6.

10.

MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.

Paulson AK, Linklater ES, Berghuis BD, App CA, Oostendorp LD, Paulson JE, Pettinga JE, Melnik MK, Vande Woude GF, Graveel CR.

Mol Cancer Res. 2013 Sep;11(9):1112-21. doi: 10.1158/1541-7786.MCR-13-0042. Epub 2013 Jul 3.

11.

MET: a critical player in tumorigenesis and therapeutic target.

Graveel CR, Tolbert D, Vande Woude GF.

Cold Spring Harb Perspect Biol. 2013 Jul 1;5(7). pii: a009209. doi: 10.1101/cshperspect.a009209. Review.

12.

Wnt/β-catenin Signaling in Normal and Cancer Stem Cells.

Valkenburg KC, Graveel CR, Zylstra-Diegel CR, Zhong Z, Williams BO.

Cancers (Basel). 2011 Apr 19;3(2):2050-79. doi: 10.3390/cancers3022050.

13.

Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.

Graveel CR, DeGroot JD, Sigler RE, Vande Woude GF.

PLoS One. 2010 Oct 25;5(10):e13586. doi: 10.1371/journal.pone.0013586.

14.

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Graveel CR, DeGroot JD, Su Y, Koeman J, Dykema K, Leung S, Snider J, Davies SR, Swiatek PJ, Cottingham S, Watson MA, Ellis MJ, Sigler RE, Furge KA, Vande Woude GF.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12909-14. doi: 10.1073/pnas.0810403106. Epub 2009 Jun 30.

15.

A mouse model of activating Met mutations.

Graveel CR, London CA, Vande Woude GF.

Cell Cycle. 2005 Apr;4(4):518-20. Epub 2005 Apr 7. Review.

PMID:
15738649
16.

Identification and characterization of CRG-L2, a new marker for liver tumor development.

Graveel CR, Harkins-Perry SR, Acevedo LG, Farnham PJ.

Oncogene. 2003 Mar 20;22(11):1730-6.

PMID:
12642876
17.

The identification of E2F1-specific target genes.

Wells J, Graveel CR, Bartley SM, Madore SJ, Farnham PJ.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3890-5.

18.

Expression profiling and identification of novel genes in hepatocellular carcinomas.

Graveel CR, Jatkoe T, Madore SJ, Holt AL, Farnham PJ.

Oncogene. 2001 May 10;20(21):2704-12.

19.

No effect of loss of E2F1 on liver regeneration or hepatocarcinogenesis in C57BL/6J or C3H/HeJ mice.

Lukas ER, Bartley SM, Graveel CR, Diaz ZM, Dyson N, Harlow E, Yamasaki L, Farnham PJ.

Mol Carcinog. 1999 Aug;25(4):295-303.

PMID:
10449036

Supplemental Content

Loading ...
Support Center